Today's Rundown | Welcome to Fierce’s daily coronavirus roundup. In order to bring you the most comprehensive and up-to-date information relating to the pandemic, we are publishing additional stories and all of the day’s coronavirus-related news in a PM edition. If you would prefer not to receive this newsletter, you may opt out at any time by clicking here. | |
|
Featured Story | | | Friday, March 20, 2020 As the biotech industry tries to match the pace of the COVID-19 pandemic with its own research response, we at FierceBiotech are rounding up the industry’s attempts to combat the virus after infection. |
|
|---|
|
Top Stories Friday, March 20, 2020 The hunt is well underway for medicines to combat COVID-19, but it will be longer for vaccines than it will be for drug treatments. Here’s a guide to the 35 vaccines in development against COVID-19, including Moderna Therapeutics' phase 1 RNA shot, Pfizer and BioNTech's candidate hard on its heels and a host of preclinical prospects. Friday, March 20, 2020 Little or no protective equipment. No testing abilities. Fears of losing their practices. Staffing outages. Phone lines flooded with patients concerned about coronavirus. Primary care practices are being hard hit by the coronavirus outbreak and many physicians describe desperate conditions, according to a new survey. Friday, March 20, 2020 After two weeks of sleepless nights, growing comfort with conference calls and "esprit de corps," Regeneron researchers are making headway toward a COVID-19 therapy with the backing of international regulators and a "shared sense of urgency," said David Weinreich, Regeneron's head of global clinical development, on Friday. Friday, March 20, 2020 In the wake of the global pandemic, hospital system finances are taking a beating. Thursday, March 19, 2020 FierceHealthcare's ongoing coverage of how the coronavirus is impacting the healthcare industry. Friday, March 20, 2020 AACR is the latest annual meeting to either be rescheduled or canceled. Following moves by Mylan and Teva to bolster chloroquine supplies, Novartis pledged a major donation. And new FDA guidance encourages more patient monitoring from home. Friday, March 20, 2020 A Biogen employee who allegedly concealed her coronavirus symptoms on a flight back to China may face criminal charges. But first, the biotech has decided it wants nothing to do with the rogue staffer. “She is no longer an employee of Biogen,” the biotech said in a statement. Friday, March 20, 2020 As efforts to discover new COVID-19 medicines roll on, President Donald Trump and others this week focused attention on the decades-old malaria drug chloroquine. Bayer got things rolling with an initial donation of the drug, and now Novartis, Mylan and Teva are taking steps to deliver tens of millions of tablets. Friday, March 20, 2020 Looking for support? Here's a roundup of some of the free healthcare resources available in midst of COVID-19 Friday, March 20, 2020 As the COVID-19 outbreak continues, health plans are evolving their response in tandem. Friday, March 20, 2020 While there is no business as usual anymore, pharma marketing is mostly staying the course for now in the shadow of COVID-19. A survey of ad agencies and communications firms that handle pharma clients found both slowdowns and bright spots, but mostly lots of question marks as the situation continues to unfold. Friday, March 20, 2020 Using a regulatory pathway that allows patients with life-threatening conditions to use unapproved therapies, the FDA has granted “emergency expanded access” to Bellerophon Therapeutics’ inhaled nitric oxide delivery system for treating the novel coronavirus. Friday, March 20, 2020 Moleculin Biotech is set to test its glucose decoy prodrug WP1122 as a treatment for the coronavirus. The plan is underpinned by evidence the drug may starve infected cells of energy while also exposing the COVID-19 virus to immune attacks. |
|
